Pfizer’s Zavzpret received US FDA approval for the acute treatment of migraine in adult patients with or without aura. Credit: Usman Yousaf / Pixabay.

The US Food and Drug Administration (FDA) has granted approval for Pfizer’s Zavzpret (zavegepant) for the acute treatment of migraine in adult patients with or without aura.

Zavzpret is claimed to be the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray approved to treat migraine.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is a third-generation, selective and structurally unique, small molecule CGRP receptor antagonist and is currently under clinical development with oral and intranasal formulations.

The company stated that the regulatory approval expands its migraine portfolio, which includes oral therapy for acute and preventive treatment.

Pfizer Global Biopharmaceuticals Business president and chief commercial officer Angela Hwang said: “The FDA approval of Zavzpret marks a significant breakthrough for people with migraine who need freedom from pain and prefer alternative options to oral medications.

“Zavzpret underscores Pfizer’s commitment to delivering an additional treatment option to help people with migraine gain relief and get back to their daily lives.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Pfizer will continue to build its migraine franchise to further support the billions of people worldwide impacted by this debilitating disease.”

The regulator granted the approval based on two pivotal placebo-controlled, double-blind, randomised trials.

These trials established Zavzpret’s safety, tolerability and efficacy profiles for acute migraine treatment.

The CGRP receptor antagonist was found to be statistically superior to placebo on the co-primary endpoints of pain freedom and freedom from most bothersome symptoms two hours after the dose in the two trials.

The company expects to launch Zavzpret in pharmacies in July.